LifeCell Corporation (LIFC) Corp. Sheet
Related News: Stem Cell CompaniesCorporate Summary (site quote):
LifeCell is a leader in the development and commercialization of human-derived tissue based products for use in reconstructive, urogynecologic and orthopedic surgical procedures. The Company's patented technology produces a unique regenerative human tissue matrix—binding sites and vascular channels—that provides a complete template for the regeneration of normal human tissue. LifeCell's current products include: AlloDerm®, for plastic reconstructive, general surgical, burn and periodontal procedures; Cymetra®, a particulate form of AlloDerm suitable for injection; Repliform®, for urogynecologic surgical procedures; GraftJacket®, for orthopedic surgical procedures; and AlloCraft DBM, for bone grafting procedures.
Intrinsic tissue regeneration in the body
Intrinsic tissue regeneration is the body’s regular maintenance cycle in which millions of tissue cells constantly undergo remodeling and restoration. It begins with circulating mesenchymal stem cells originating from bone marrow. Biochemical signals draw the stem cells to sites where growth factors have created an environment for regeneration.
AlloDerm parallels nature. In fact, it is the ideal biological framework to harness nature’s own regenerative healing process.
During the regeneration process, the AlloDerm matrix becomes part of the existing tissue structure in four stages:
1. The circulating stem cells target damaged tissue
2. In the target area, these cells deposit and adhere to the matrix
3. Next, the cells differentiate into tissue-specific cell types
4. Finally, the differentiated cells elaborate the new matrix to regenerate tissue
Posted on January 21, 2005 04:17 PM